Natco Pharma is currently trading at Rs. 536.80, up by 3.20 points or 0.60% from its previous closing of Rs. 533.60 on the BSE.
The scrip opened at Rs. 538.00 and has touched a high and low of Rs. 541.80 and Rs. 532.35 respectively. So far 1126 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 849.00 on 12-Sep-2018 and a 52 week low of Rs. 520.00 on 30-Apr-2019.
Last one week high and low of the scrip stood at Rs. 553.95 and Rs. 520.00 respectively. The current market cap of the company is Rs. 9790.61 crore.
The promoters holding in the company stood at 48.71%, while Institutions and Non-Institutions held 28.52% and 22.77% respectively.
Natco Pharma has received final approval of Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (USFDA) for Bosentan tablets in the strengths of 62.5 mg and 125 mg.
Bosentan is used for the treatment of patients with pulmonary arterial hypertension. The tablets of Natco marketing by its partner Lupin are a generic version of Actelion Pharmaceuticals’ Tracleer tablets in the same strengths.
As per IQVIA MAT March 2019 data, Bosentan tablets 62.5 mg and 125 mg had an annual sales of around $84.8 million in the US market.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
